Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 16:00 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
VIC-1911 Monotherapy in Combination With Sotorasib for the Treatment of KRAS G12C-Mutant Non-Small Cell Lung Cancer
NCT05374538 · Vitrac Therapeutics, LLC · PHASE1 · terminated · last registry update 2025-05-01 · Non-small cell lung cancer · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Sponsor decision” | Open Targets' class: business administrative | Registry record, Vitrac Therapeutics, LLC |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against KRAS in non-small cell lung cancer within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2026-04-09Also stopped (terminated): M.D. Anderson Cancer Center, Adagrasib + Olaparib (NCT06130254)
- 2026-04-08Also stopped (terminated): Deciphera Pharmaceuticals, LLC, Inlexisertib + Trametinib (NCT04892017)
- 2026-02-19Also stopped (terminated): Mirati Therapeutics Inc., MRTX0902 + MRTX849 (NCT05578092)
- 2026-01-06Results posted on the registry: Revolution Medicines, Inc., RMC-4630 + Sotorasib (NCT05054725)
- 2025-12-16Results posted on the registry: Medical University of South Carolina, Sotorasib and Tarloxotinib + Sotorasib and Tarloxotinib (NCT05313009)
- 2025-12-16Also stopped (terminated): Medical University of South Carolina, Sotorasib and Tarloxotinib + Sotorasib and Tarloxotinib (NCT05313009)
- 2025-09-15Also stopped (withdrawn): Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Adagrasib + Adagrasib/Nivolumab (NCT05472623)
- 2025-04-25Also stopped (terminated): Mirati Therapeutics Inc., Adagrasib + nab-Sirolimus (NCT05840510)
- 2025-03-13Phase 3 first posted: Mirati Therapeutics Inc., Adagrasib + Pembrolizumab (NCT06875310)
- 2025-01-22Results posted on the registry: Mirati Therapeutics Inc., MRTX849 + Docetaxel (NCT04685135)
- 2024-12-12Also stopped (terminated): Navire Pharma Inc., a BridgeBio company, BBP-398 + sotorasib (NCT05480865)
- 2024-11-20Also stopped (withdrawn): ETOP IBCSG Partners Foundation, Sotorasib + Lenvatinib (NCT06068153)
- 2024-07-11Phase 3 first posted: Hoffmann-La Roche, Divarasib + Sotorasib (NCT06497556)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision